Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional

Effect of 2-year Administration of CP-945,598 on Weight Loss Efficacy and Safety.

ClinicalTrials.gov ID: NCT00396448

Public ClinicalTrials.gov record NCT00396448. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 1:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 2-Year, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study To Evaluate The Long-Term Efficacy And Safety Of CP-945,598 In The Treatment Of Obese Subjects

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to examine the long-term weight loss and safety of CP-945,598 in obese adults

Study identification

NCT ID
NCT00396448
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
1,253 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2007
Primary completion
Jan 31, 2009
Completion
Jan 31, 2009
Last update posted
Nov 6, 2012

2007 – 2009

United States locations

U.S. sites
15
U.S. states
12
U.S. cities
15
Facility City State ZIP Site status
Pfizer Investigational Site Peoria Arizona 85381
Pfizer Investigational Site Newport Beach California 92660-2452
Pfizer Investigational Site Miami Florida 33143
Pfizer Investigational Site Springfield Illinois 62704
Pfizer Investigational Site Overland Park Kansas 66202
Pfizer Investigational Site Louisville Kentucky 40217
Pfizer Investigational Site Farmington Hills Michigan 48336
Pfizer Investigational Site Cary North Carolina 27518
Pfizer Investigational Site Raleigh North Carolina 27609
Pfizer Investigational Site Wilmington North Carolina 28401
Pfizer Investigational Site Winston-Salem North Carolina 27103
Pfizer Investigational Site Portland Oregon 97210
Pfizer Investigational Site Anderson South Carolina 29621
Pfizer Investigational Site Johnson City Tennessee 37601
Pfizer Investigational Site Bountiful Utah 84010

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 46 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00396448, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 6, 2012 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00396448 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →